Open Access

Wnt signalling in mammary carcinogenesis

  • Valerie Speirs1
Breast Cancer Research20024:169

DOI: 10.1186/bcr544

Published: 1 August 2002

The Wnt family consists of secreted glycoproteins expressed by a number of different tissues including the mammary gland. They are multi-functional proteins controlling diverse cellular events such as proliferation, polarity, differentiation and organogenesis. Wnt ligands bind to the extracellular cysteine-rich domain of the Frizzled family of receptors. Activation of the Wnt signalling pathway is a common feature of a number of human cancers, and culminates in the cytosolic stabilisation of ß-catenin, a transcriptional co-factor. However, there is still some uncertainty regarding just how important Wnt signalling is in breast cancer.

Two new findings provide strong evidence for the importance of Wnts in breast cancer development. Ugolini et al. [1] studied the expression pattern of secreted Frizzled-related protein (SFRP1) mRNA in breast cancers. SFRP1 encodes a protein that contains a cysteine-rich domain similar to the Wnt-binding site of Frizzled receptors and is a secreted inhibitor of Wnt signal transduction. They found that SFRP1 was expressed in normal mammary gland but lost in more than 80% of tumours. In other words, loss of an inhibitor of the pathway correlated with both activation of the pathway and breast cancer formation. In a related article, Jonsson et al. [2] adopted a more direct approach by exploring the clinical relevance of immunohistochemical expression of a member of the Wnt family, Wnt-5a, in primary invasive carcinomas. Loss of Wnt-5a was associated with poorer prognosis and increased risk of relapse.

These two articles add weight to the hypothesis that the Wnt pathway is important in breast carcinogenesis and warrants further research. Wnt-5a in particular may be important in a diagnostic setting as a clinical marker of an aggressive tumour phenotype and predictor of disease recurrence.

Other recently published research of interest is listed in the references [310].

Authors’ Affiliations

(1)
Molecular Medicine Unit, University of Leeds

References

  1. Ugolini F, Charafe-Jauffret E, Bardou VJ, Geneix J, Adelaide J, Labat-Moleur F, Penault-Llorca F, Longy M, Jacquemier J, Birnbaum D, et al: Wnt pathway and mammary carcinogenesis: Loss of expression of candidate tumour suppressor gene SFRP1 in most invasive carcinomas except of the medullary type. Oncogene. 2001, 20: 5810-5817. 10.1038/sj.onc.1204706. For the Faculty of 1000 evaluation of this article please see http://breast-cancer-research.com/reports/bcr6_02.asp#ugolini View ArticlePubMedGoogle Scholar
  2. Jonsson M, Dejmek J, Bendahl PO, Andersson T: Loss of Wnt-5a protein is associated with early relapse in invasive ductal breast carcinomas. Cancer Res. 2002, 62: 409-416. For the Faculty of 1000 evaluation of this article please see http://breast-cancer-research.com/reports/bcr6_02.asp#jonsson PubMedGoogle Scholar
  3. Ji L, Nishizaki M, Gao B, Burbee D, Kondo M, Kamibayashi C, Xu K, Yen N, Atkinson EN, Fang B, et al: Expression of several genes in the human chromosome 3p21.3 homozygous deletion region by an adenovirus vector results in tumour suppressor activities in vitro and in vivo. Cancer Res. 2002, 62: 2715-2720. For the Faculty of 1000 evaluation of this article please see http://breast-cancer-research.com/reports/bcr6_02.asp#ji PubMedPubMed CentralGoogle Scholar
  4. Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M, de Snoo A, Oldenburg R, Hollestelle A, Houben M, Crepin E, van Veghel-Plandsoen M, et al: Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in non-carriers of BRCA1 or BRCA2 mutations. Nat Genet. 2002, 31: 55-59. 10.1038/ng879. For the Faculty of 1000 evaluation of this article please see http://breast-cancer-research.com/reports/bcr6_02.asp#meijers View ArticlePubMedGoogle Scholar
  5. Ritchie MD, Hahn LW, Roodi N, Bailey LR, Dupont WD, Parl FF, Moore JH: Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer. Am J Hum Genet. 2001, 69: 138-147. 10.1086/321276. For the Faculty of 1000 evaluation of this article please see http://breast-cancer-research.com/reports/bcr6_02.asp#ritchie View ArticlePubMedPubMed CentralGoogle Scholar
  6. Scott SP, Bendix B, Chen P, Clark R, Dork T, Lavin MF: Missense mutations but not allelic variants alter the function of ATM by dominant interference in patients with breast cancer. Proc Natl Acad Sci USA. 2002, 99: 925-930. 10.1073/pnas.012329699. For the Faculty of 1000 evaluation of this article please see http://breast-cancer-research.com/reports/bcr6_02.asp#scott View ArticlePubMedPubMed CentralGoogle Scholar
  7. Chenevix-Trench G, Spurdle AB, Gatei M, Kelly H, Marsh A, Chen X, Donn K, Cummings M, Nyholt D, Jenkins MA, et al: Dominant negative ATM mutations in breast cancer families. J Natl Cancer Inst. 2002, 94: 205-215. 10.1093/jnci/94.3.205. For the Faculty of 1000 evaluation of this article please see http://breast-cancer-research.com/reports/bcr6_02.asp#chenevix View ArticlePubMedGoogle Scholar
  8. Rodier A, Montagnoli A, Di Marcotullio L, Coulombe P, Draetta GF, Pagano M, Meloche S: p27 cytoplasmic localization is regulated by phosphorylation on Ser10 and is not a prerequisite for its proteolysis. EMBO J. 2001, 20: 6672-6682. 10.1093/emboj/20.23.6672. For the Faculty of 1000 evaluation of this article please see http://breast-cancer-research.com/reports/bcr6_02.asp#rodier View ArticlePubMedPubMed CentralGoogle Scholar
  9. Williams RS, Green R, Glover JN: Crystal structure of the BRCT repeat region from the breast cancer-associated protein BRCA1. Nat Struct Biol. 2001, 8: 838-842. 10.1038/nsb1001-838. For the Faculty of 1000 evaluation of this article please see http://breast-cancer-research.com/reports/bcr6_02.asp#williams View ArticlePubMedGoogle Scholar
  10. Strohmaier H, Spruck CH, Kaiser P, Won KA, Sangfelt O, Reed SI: Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line. Nature. 2001, 413: 316-322. 10.1038/35095076. For the Faculty of 1000 evaluation of this article please see http://breast-cancer-research.com/reports/bcr6_02.asp#strohmaier View ArticlePubMedGoogle Scholar
  11. Note

    1. This article is based on papers highlighted by Faculty of 1000 http://www.facultyof1000.com/start.asp a web-based literature awareness service. Faculty of 1000 evaluations available for articles cited in this report may be viewed at: http://breast-cancer-research.com/reports/bcr6_02.asp

Copyright

© BioMed Central Ltd 2002

Advertisement